Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma

European Journal of Cancer Part A

Volumn 33, Issue 2, 1997, Pages 307-311

  Young, R I ^a   Ranson, M ^a   Chang, J ^b   Lord, B ^a   Testa, N ^a   Scarffe, J H ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Interleukin 6; Multiple myeloma

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; RECOMBINANT INTERLEUKIN 6; VINCRISTINE;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; DEXAMETHASONE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECOMBINANT PROTEINS; VINCRISTINE;

EID: 0030973669     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00383-8     Document Type: Article

References (22)

1. Klein B, Zhang X-G, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995, 85, 863-872.
2. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF/IL-6 for human multiple myeloma. Nature 1988, 332, 83-85.
3. Klein B, Zhang X-G, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by interleukin-6. Blood 1989, 73, 517-521.
4. Cannistra SA, Dicarlo J, Groshek P, et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukaemia. Leukaemia 1991, 5, 230-238.
5. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alfa-2a interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989, 7, 1769-1775.
6. Veldhuis GJ, Willemse PH, Sleijfer DT, et al. Toxicity and efficacy of escalating dosages of recombinant human IL-6 after chemotherapy in patients with breast cancer or non-small cell lung cancer. J Clin Oncol 1995, 13, 2585-2593.
7. Lazarus HM, Winton EF, Williams SF, et al. Phase I multicentre trial of interleukin-6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant 1995, 15, 935-942.
8. Gordon MS, Nemunaitis J, Hoffman R, et al. A phase I trial of recombinant II-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995, 85, 3066-3076.
9. Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe JH, Stern PL. Immune function of patients receiving recombinant human IL-6 in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and LAK cell activity. Cancer Immunol Immunother 1994, 38, 119-126.
10. van Gameren MM, Willemse PH, Mulder PH, et al. Effects of human IL-6 in cancer patients: a phase I-II study. Blood 1994, 84, 1434-1441.
11. Estey E, Andreeff M. Phase II study of IL-6 in patients with smouldering relapse of acute myelogenous leukaemia. Leukaemia 1995, 9, 1440-1443.
12. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310, 1353-1356.
13. Anderson H, Scarffe JH, Ranson M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995, 71, 326-330.
14. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975, 36, 842-854.
15. Chronic Leukaemia Task Force. Proposed guide-lines for protocol studies II. Plasma cell myeloma. Cancer Chemother Rep 1973, 4, 145-157.
16. Gore ME, Viner C, Meldrum M, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989, ii, 879-885.
17. Nicken J, Mulder NH, Buter J, et al. Recombinant human IL-6 induces a rapid and reversible anaemia in cancer patients. Blood 1995, 86, 900-905.
18. Atkins MB, Kappler K, Mier JW, Isaacs RE, Berkman EM. IL-6 associated anaemia: determination of the underlying mechanism. Blood 1995, 86, 1288-1291.
19. Bataille R, Jourdan M, Zhang X-G, Klein R. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989, 84, 2008-2011.
20. Pelliniemi T-T, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995, 85, 765-771.
21. Tanabe O, Kawano M, Tanaka H, et al. BSF-2/IL-6 does not augment Ig secretion but stimulates proliferation in myeloma cells. Am J Haematol 1989, 31, 258-262.
22. Iwato K, Kawano M, Asaoku H, et al. Separation of human myeloma cells from bone marrow aspirates in multiple myeloma and their proliferation and M-protein secretion in vitro. Blood 1988, 72, 562-566.